Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.

Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, Burger ZC, Rawlings SA, Smith DM, Phillips E, Mallal S, Lammers M, Rubiro P, Quiambao L, Sutherland A, Yu ED, da Silva Antunes R, Greenbaum J, Frazier A, Markmann AJ, Premkumar L, de Silva A, Peters B, Crotty S, Sette A, Weiskopf D. · 2020

Read Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. by Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, Burger ZC, Rawlings SA, Smith DM, Phillips E, Mallal S, Lammers M, Rubiro P, Quiambao L, Sutherland A, Yu ED, da Silva Antunes R, Greenbaum J, Frazier A, Markmann AJ, Premkumar L, de Silva A, Peters B, Crotty S, Sette A, Weiskopf D. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7574914.txt.

Introduction

Mateus and co-authors study cross-reactive T cell epitopes for SARS-CoV-2 in unexposed people. Strong T cell responses occur in most COVID-19 cases. Some unexposed people also showed reactivity to the virus.

Earlier reports put that share at 20 to 50%. The team traced the reactivity to memory T cells. Cross-reactive cells recognized one SARS-CoV-2 epitope clearly. They also recognized the matching epitope from a common cold virus. Prior cold coronavirus exposure may explain the pattern. Most reactivity came from CD4+ T cells. The findings stress checking prior immune memory. Such memory may shape disease severity in new infections.

Catalog record

CREATORMateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, Burger ZC, Rawlings SA, Smith DM, Phillips E, Mallal S, Lammers M, Rubiro P, Quiambao L, Sutherland A, Yu ED, da Silva Antunes R, Greenbaum J, Frazier A, Markmann AJ, Premkumar L, de Silva A, Peters B, Crotty S, Sette A, Weiskopf D.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE42 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7574914

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans By Jose Mateus, Alba Grifoni, Alison Tarke, John Sidney, Sydney I Ramirez, Jennifer M Dan, Zoe C Burger, Stephen A Rawlings, Davey M Smith, Elizabeth Phillips, Simon Mallal, Marshall Lammers Published in: Science (New York, N.y.) DOI: 10.1126/science.abd3871 ABSTRACT Preexisting immune response to SARS-CoV-2 Robust T cell responses to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus occur in most individuals with coronavirus disease 2019 (COVID-19). Several studies have reported that some people who have not been exposed to SARS-CoV-2 have preexisting reactivity to SARS-CoV-2 sequences. The immunological mechanisms underlying this preexisting reactivity are not clear, but previous exposure to widely circulating common cold coronaviruses might be involved. Mateus et al. found that the preexisting reactivity against SARS-CoV-2 comes from memory T cells and that cross-reactive T cells can specifically recognize a SARS-CoV-2 epitope as well as the homologous epitope from a common cold coronavirus. These findings underline the importance of determining the impacts of preexisting immune memory in COVID-19 disease severity. Science, this issue p. 89 The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019 and its subsequent global spread has led to millions of infections and substantial morbidity and mortality (1). Coronavirus disease 2019 (COVID-19), the clinical disease caused by SARS-CoV-2 infection, can range from mild, self-limiting disease to acute respiratory distress syndrome and death (2). The mechanisms underlying the spectrum of COVID-19 disease severity states and the nature of protective immunity against COVID-19 remain unclear. Studies investigating the human immune response against SARS-CoV-2 have begun to characterize SARS-CoV-2 antigen-specific T cell responses (3–8), and multiple studies have described marked activation of T cell subsets in acute COVID-19 patients (9–13). Unexpectedly, antigen-specific T cell studies performed with five different cohorts reported that 20 to 50% of people who had not been exposed to SARS-CoV-2 had significant T cell reactivity directed against peptides corresponding to SARS-CoV-2 sequences (3–7). The studies were from geographically diverse cohorts (the United States, the Netherlands, Germany, Singapore, and the United Kingdom), and the general pattern observed was that the T cell reactivity found in unexposed individuals was predominantly mediated by CD4+ T cells. It was speculated that this phenomenon might be due to preexisting memory responses against human “common cold” coronaviruses (HCoVs) such as HCoV-OC43, HCoV-HKU1, HCoV-NL63, and HCoV-229E. These HCoVs share partial sequence homology with SARS-CoV-2, are widely circulating in the general population, and are typically responsible for mild respiratory symptoms (14–16). However, the hypothesis of cross-reactive immunity between SARS-CoV-2 and common cold HCoVs still awaits experimental trials. This potential preexisting cross-reactive T cell immunity to SARS-CoV-2 has broad implications because it could explain aspects of differential COVID-19 clinical outcomes, influence epidemiological models of herd immunity (17, 18), or affect the performance of COVID-19 candidate vaccines. EPITOPE REPERTOIRE IN SARS-COV-2–UNEXPOSED INDIVIDUALS To define the repertoire of CD4+ T cells recognizing SARS-CoV-2 epitopes in previously unexposed individuals, we used in vitro stimulation of peripheral blood mononuclear cells (PBMCs) for 2 weeks with pools of 15-mer peptides. This method is known to be robust for detecting low-frequency T cell responses to allergens and bacterial or viral antigens (19, 20), including naive T cells (21). For screening SARS-CoV-2 epitopes, we used PBMC samples from unexposed subjects collected between March 2015 and March 2018, well before the global circulation of SARS-CoV-2 occurred. The unexposed subjects were confirmed to be seronegative for SARS-CoV-2 (fig. S1A). SARS-CoV-2–reactive T cells were expanded, with one pool of peptides spanning the entire sequence of the spike protein (CD4-S) and the other a nonspike “megapool” (CD4-R) of predicted epitopes from the nonspike regions (i.e., “remainder”) of the viral genome (4). In total, 474 15-mer SARS-CoV-2 peptides were screened. After 14 days of stimulation, T cell reactivity against intermediate “mesopools,” each encompassing ~10 peptides, was assayed using a FluoroSPOT assay (e.g., 22 CD4-R mesopools; fig. S2A). Positive mesopools were further deconvoluted to identify specific individual SARS-CoV-2 epitopes. Representative results from one donor show the deconvolution of mesopools P6 and P18 to identify seven different SARS-CoV-2 epitopes (fig. S2B). Intracellular cytokine-staining assays specific for interferon γ (IFN-γ) determined whether antigen-specific T cells responding to the SARS-CoV-2 mesopools were CD4+ or CD8+ T cells (fig. S2C). Results from the 44 donors/CD4-R mesopool and 40 donors/CD4-S mesopool combinations yielding a positive response are shown in fig. S2, D and E, respectively. In 82/88 cases (93.2%), the cells responding to SARS-CoV-2 mesopool stimulation were clearly CD4+ T cells, as judged by the ratio of CD4/CD8–responding cells; in four cases (4.5%), the responding cells were CD8+ T cells; and in two cases (2.3%), the responses were mediated by both CD4+ and CD8+ T cells. The fact that CD8+ T cells were rarely detected was not surprising because the peptides used in CD4-R encompassed predicted class II epitopes and the CD4-S is composed of 15-mer peptides (9- to 10-mer peptides are optimal for CD8+ T cells). Furthermore, the 2-week restimulation protocol was originally designed to expand CD4+ T cells (20). Overall, these results indicated that the peptide-screening strategy used mapped SARS-CoV-2 epitopes recognized by CD4+ T cells in unexposed individuals. A total of 142 SARS-CoV-2 epitopes were identified, 66 from the spike protein (CD4-S) and 76 from the remainder of the genome (CD4-R) (table S1). For each combination of epitope and responding donor, potential human leukocyte antigen (HLA) restrictions were inferred on the basis of the predicted HLA-binding capacity of the particular epitope for the specific HLA alleles present in the responding donor (22). Each donor recognized an average of 11.4 epitopes (range 1 to 33, median 6.5; fig. S3A). Forty of the 142 epitopes were recognized by two or more donors (fig. S3B), accounting for 55% of the total response (fig. S3C). These 142 mapped SARS-CoV-2 epitopes may prove useful in future studies as reagents for tracking CD4+ T cells in SARS-CoV-2–infected individuals and in COVID-19 vaccine trials. EPITOPE DISTRIBUTION BY ORF OF ORIGIN Although a broad range of different SARS-CoV-2 antigens were recognized, several of the epitopes yielding the most frequent (i.e., recognized in multiple donors) or most vigorous [i.e., the most spot-forming cells (SFCs)/106 cells] responses were derived from the SARS-CoV-2 spike antigen (table S1). We therefore assessed the overall distribution of the 142 T cell epitopes mapped among all SARS-CoV-2 proteins compared with the relative size of each SARS-CoV-2 antigen (Fig. 1, A and B). Fifty-four percent of the total positive response was associated with spike-derived epitopes [Fig. 1A; 11% for receptor-binding domain (RBD), and 44% for the non-RBD portion of spike]. Of relevance for COVID-19 vaccine development, only 20% of the spike responses were derived from the RBD region (Fig. 1A; comparing 11 versus 44%, as described above), and the RBD region accounted for only 11% of the overall CD4+ T cell reactivity (Fig. 1A). Mapped epitopes were fairly evenly distributed across the SARS-CoV-2 genome in proportion to the size of each protein (Fig. 1B; P = 0.038, r = 0.42). In addition to the strong responses directed to spike, responses were also seen for open reading frame 6 (ORF6), ORF3a, N, ORF8, and within Orf1a/b, where nsp3, nsp12, nsp4, nsp6, nsp2, and nsp14 were more prominently recognized. These mapped

Read the complete text